Overview
CellMosaic® is a platform technology company dedicated to creating high-quality, innovative, and advanced bioconjugates. Bioconjugates are used broadly as research tools, diagnostic reagents, and a novel modality for drugs, such as antibody-drug conjugates (ADCs). Since its establishment in 2008, CellMosaic® has spent a lot of research effort on developing innovative linkers, crosslinking technologies, and advanced conjugation processes. CellMosaic® currently offers bioconjugation related reagents/kits, customer bioconjugation services, contract bioconjugate development and manufacturing, and partnering to develop proprietary innovative AqT® ADC using its proprietary AqT® linker modified drugs.
AqT® linkers are novel proprietary biomaterials with innovative chemical architectures invented at CellMosaic based on a class of natural and edible sugar alcohol compounds. AqT® molecules are designed for labeling and conjugating biomolecules with very hydrophobic small-molecule drugs. Branched AqT® crosslinking reagents can also be designed to allow high amounts of drugs to be loaded onto a single targeting biomolecule such as antibody for high potency or combination treatment. The AqT® platform can significantly accelerate the drug discovery process to deliver an optimized entity for development. It provides a broadly applicable approach to developing a new chemical entity (NCE) or new biological entity (NBE) with optimized drug profiles. The AqT® platform offers a simple solution to complicated bioavailability, stability, and/or toxicity issues faced by many small-molecule hydrophobic drugs, as well as with large-molecule biologics.